Founded in 2013 by Frank Yu, Ally Bridge Group is based in Hong Kong and New York. With a focus on healthcare, life sciences, and disruptive technology platforms in medical devices and biopharmaceuticals, the firm invests in companies in the United States, Hong Kong, and China. They have a particular interest in immuno-oncology and specialty pharma. Ally Bridge Group has a strong track record of exits and typically invests in rounds with 4-5 participants. They have additional offices in China and the United States and manage the Ally Bridge Group-WTT Global Life Science Capital Partners buyout fund.